Pioneering AIDS researcher to speak at UH

September 14, 2004

In his lecture - "AIDS: From Vaccine Research to Public Health" - Ho will speak about strides in research that have come about due to the AIDS epidemic in China, where estimates expect the total case load to reach 10 million infected with HIV by 2010.

Ho will talk about a DNA vaccine that has already reached phase-I human trial, as well as discuss two more vaccines under development. These vaccines under development are based on a viral strain common in China's southwest region. The China AIDS Initiative, a consortium of Chinese and American organizations that have come together to combine forces in advocacy, public education, testing and prevention work, and antiretroviral therapy, will also be discussed.

"It is most gratifying to have our work progress from the discovery of new knowledge to the application of old knowledge," Ho said. "To go from basic research to clinical applications to public health in the land of my heritage is especially rewarding."

Ho is the founding scientific director and CEO of the Aaron Diamond AIDS Research Center, a world-renowned biomedical research institute, the Irene Diamond Professor at The Rockefeller University and a Committee of 100 (C-100) member.

Brought to UH by C-100, a national organization composed of more than 100 of the most influential Chinese Americans in the United States, Ho's lecture is also sponsored by UH's Texas Center for Superconductivity and Advanced Materials, the Office of Houston City Council Member Gordon Quan and Leadership Education for Asian Pacifics (LEAP). The event is being held in conjunction with a daylong Asian-American professional development workshop co-hosted by LEAP and C-100 at the Houston Community College administration building.

Holding six honorary doctorates, a member of the Institute of Medicine of the National Academy of Arts and Sciences, Time magazine's 1996 "Man of the Year" and a 2001 Presidential Medal recipient, Ho has been actively engaged in AIDS research for 20 years. He continues to pursue therapeutic studies that attempt to eradicate HIV, in addition to efforts to develop a vaccine to halt the spread of the AIDS epidemic.

The lecture will be Web cast live at and archived at

David D. Ho, M.D.
World-renowned AIDS Researcher

Committee of 100 / University of Houston Distinguished Lecture

5 to 5:30 p.m. (media availability)
7:30 to 8:30 p.m. (lecture); 8:30 to 9 p.m. (meet and greet)
Saturday, Sept. 18, 2004

University of Houston Hilton Hotel
Waldorf Astoria Ballroom
4800 Calhoun Road, Entrance 1
Free Parking in Lot 1A
For more information about UH, visit the university's Newsroom at

For more information about the C-100, visit

To receive UH science news via e-mail, visit

University of Houston

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to